Of all the academic ink that's been spilled on the subject of who wins in a takeover battle, the general consensus is that it's largely the shareholders. Only time will tell whether that's true for Boston Scientific's
Assuming that no more weirdness ensures in the BSX-GDT affair, Abbott will end up acquiring Guidant's vascular business (and its R&D) for $4.1 billion. It will also buy $1.4 billion worth of BSX's stock and foot it a $900 million loan. That immediately enhances Abbott's credibility as a future player in the stent market. While Abbott's ZoMaxx stent has looked clinically interesting, not many were giving Abbott much chance of being anything more than a distant No. 4 competitor to Medtronic
But that's all still off in the future. We have earnings to discuss today.
Revenue in the fourth quarter climbed 7%, and operating income rose by more than 15%. As seems to be the case all the time these days, there were charges, gains, add-backs, and assorted detritus in the earnings numbers. Giving Abbott the benefit of the doubt, we should also note that gross margins perked up a bit and earnings per share rose by more than 13%.
There was respectable growth across the board, but pharmaceuticals still account for the majority of revenue. Here it was a case of the strong getting stronger, as Abbott's top drug, HUMIRA, continues to enjoy very good growth. Elsewhere, the diabetes business made a solid showing, while the nutrition sector was down versus last year.
Abbott has a reputation for being a steady-Eddy type of company -- not a lot of flashy growth or high-risk/high-reward products, but a reliable history of earnings and cash flow growth. But that's not to say the cupboard is bare -- HUMIRA is proving to have long legs indeed, and more distant products -- like a continuous blood glucose monitor and a drug-eluting stent -- combine with what could prove to be an underrated drug pipeline.
We're still in the midst of that annual move in the stock below a P/E of 20, but I'm not sure how long that'll last. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry.
Fool contributor Stephen Simpson has no financial interest in any stocks mentioned (that means he's neither long nor short the shares).
More from The Motley Fool
What's the Best Age to Claim Social Security? It Depends on Your Health
The state of your health needs to be a driving factor in deciding when to take benefits. Here's why.
3 Fools, 1 Deep Dive Into the Disney/Fox Deal
Even for a media company as acquisitive as Disney, the assets it's picking up in this $52.4 billion purchase are major.
3 Dividend Stocks With Better Yields Than Johnson & Johnson
These stocks would serve your income portfolio better than Johnson & Johnson today.